Immune checkpoint blockade (ICB) is efficacious in many diverse cancer types, but not all
patients respond. It is important to understand the mechanisms driving resistance to these …

The therapeutic response to immune checkpoint blockade (ICB) is highly variable, not only
between different cancers but also between patients with the same cancer type. The …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment, providing
remarkable clinical responses in some patients. However, the majority of patients do not …

Cancer immunotherapy with monoclonal antibodies directed against regulatory pathways in
T lymphocytes has been revolutionizing medical oncology, and the clinical success of …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Immune checkpoints are a diverse set of inhibitory signals to the immune system that play a
functional role in adaptive immune response and self-tolerance. Dysregulation of these …

Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …

Immune checkpoint blockade (ICB) has significant clinical activity in diverse cancer classes
and can induce durable remissions in even refractory advanced disease. However, only a …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Recent advances in the understating of tumor immunology suggest that cancer
immunotherapy is an effective treatment against various types of cancer. In particular, the …